Table 4.
Comparison of 5-year overall survival characteristics between the PRE group and the PAS group.
| 5-year overall survival | 1994–2006 (PRE group) | 2007–2019 (PAS group) | ||||
|---|---|---|---|---|---|---|
| Characteristics | Odd ratio | 95% confidence interval | P-value | Odd Ratio | 95% confidence interval | P-value |
| Age | ||||||
| <40 | 1.528 | (0.918–2.547) | 0.108 | 1.305 | (0.892–1.937) | 0.18 |
| 40–49 | 1.671 | (1.058–2.630) | 0.028 | 1.3 | (0.942–1.791) | 0.116 |
| 50–59 | Reference | Reference | ||||
| ≥60 | 1.403 | (0.977–2.013) | 0.06 | 1.418 | (1.111–1.818) | 0.006 |
| Gender | ||||||
| Male, n (%) | Reference | Reference | ||||
| Female, n (%) | 0.983 | (0.723–1.336) | 0.938 | 1.277 | (1.028–1.586) | 0.031 |
| Hospitalization | ||||||
| ≤8, n (%) | Reference | Reference | ||||
| 9–15, n (%) | 0.795 | (0.374–1.725) | 0.571 | 1.407 | (1.104–1.790) | 0.006 |
| >15, n (%) | 1.157 | (0.524–2.624) | 0.725 | 2.31 | (1.673–3.172) | <0.0001 |
| Peritoneal metastasis | ||||||
| P0 | Reference | Reference | ||||
| P1 | 8.752 | (4.353–17.597) | <0.0001 | 9.731 | (6.128–15.453) | <0.0001 |
| Hepatic metastasis | ||||||
| H0 | Reference | Reference | ||||
| H1 | 27.302 | (3.735–199.587) | <0.0001 | 5.176 | (2.110–12.693) | <0.0001 |
| Tumor location | ||||||
| A single part of the stomach | Reference | Reference | ||||
| Two parts of the stomach | 2.258 | (1.541–3.327) | <0.0001 | 2.784 | (2.132–3.644) | <0.0001 |
| The whole stomach | 18.9 | (5.128–79.91) | <0.0001 | 8.255 | (4.499–14.900) | <0.0001 |
| Borrmann type | ||||||
| Type I | 1.343 | (0.718–2.629) | 0.375 | 2.748 | (1.458–5.228) | 0.0016 |
| Type II | Reference | Reference | ||||
| Type III | 2.773 | (1.922–3.990) | <0.0001 | 3.577 | (2.666–4.800) | <0.0001 |
| Type IV | 17.16 | (7.452–40.410) | <0.0001 | 17.09 | (10.79–26.53) | <0.0001 |
| Histological type | ||||||
| Well differentiated | Reference | Reference | ||||
| Moderately differentiated | 1.846 | (0.892–3.957) | 0.096 | 13.12 | (2.164–136.5) | 0.0005 |
| Poorly differentiated | 8.247 | (4.165–16.910) | <0.0001 | 30.85 | (5.327–318.500) | <0.0001 |
| Pathological type | ||||||
| Adenocarcinoma | 1.228 | (0.7163–2.107) | 0.4725 | 1.171 | (0.7331–1.911) | 0.5208 |
| Others | Reference | Reference | ||||
| T stage | ||||||
| T1 | Reference | Reference | ||||
| T2 | 1.545 | (0.499–4.775) | 0.425 | 2.227 | (1.124–4.271) | 0.017 |
| T3 | 8.699 | (3.948–18.31) | <0.0001 | 11.89 | (7.139–20.480) | <0.0001 |
| T4 | 19.13 | (8.919–40.05) | <0.0001 | 62.82 | (34.18–116.8) | <0.0001 |
| pTNM | ||||||
| I | Reference | Reference | ||||
| II | 5.847 | (2.743–12.540) | <0.0001 | 3.664 | (1.789–7.444) | 0.0002 |
| III | 22.26 | (9.332–49.940) | <0.0001 | 18.19 | (9.585–35.80) | <0.0001 |
| IV | 94.02 | (33.700–237.100) | <0.0001 | 166.9 | (80.640–327.700) | <0.0001 |
| N stage | ||||||
| N0 | Reference | Reference | ||||
| N1 | 7.022 | (4.603–10.712) | <0.0001 | 5.918 | (4.612–7.595) | <0.0001 |
Statistically significant results are shown in bold font. Reference: hazard ratio = 1.0. The hazard risk (HR) with a corresponding 95% confidence interval (CI) was calculated using a random-effects model.
The bold values means significant meanings.